Moderna slows coronavirus vaccine trial enrollment to ensure minority representation, CEO says

Minorities, the elderly and people with underlying health conditions are at highest risk of Covid-19, and are being prioritized for enrollment in large vaccine trials. Moderna's CEO said the company is slowing enrollment in its trial to ensure the Black community is represented.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.